Inhaled corticosteroid with short-acting β agonists or long-acting β agonist formoterol linked to reduction in exacerbations, improved control. HealthDay News — For patients with asthma, inhaled ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids. Among a cohort of patients with severe asthma using the biologic ...

Please provide your email address to receive an email when new articles are posted on . 96% of patients maintained reductions through 48 weeks. 91% of patients had no exacerbations while tapering ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...